270 related articles for article (PubMed ID: 31921126)
1. Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia.
Deak D; Pop C; Zimta AA; Jurj A; Ghiaur A; Pasca S; Teodorescu P; Dascalescu A; Antohe I; Ionescu B; Constantinescu C; Onaciu A; Munteanu R; Berindan-Neagoe I; Petrushev B; Turcas C; Iluta S; Selicean C; Zdrenghea M; Tanase A; Danaila C; Colita A; Colita A; Dima D; Coriu D; Einsele H; Tomuleasa C
Front Immunol; 2019; 10():2856. PubMed ID: 31921126
[No Abstract] [Full Text] [Related]
2. Antibody-based therapies in patients with acute lymphoblastic leukemia.
Dinner S; Liedtke M
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):9-15. PubMed ID: 30504286
[TBL] [Abstract][Full Text] [Related]
3. An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia.
Patel J; Gao X; Wang H
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108359
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges.
Jasinski S; De Los Reyes FA; Yametti GC; Pierro J; Raetz E; Carroll WL
Paediatr Drugs; 2020 Oct; 22(5):485-499. PubMed ID: 32860590
[TBL] [Abstract][Full Text] [Related]
5. Redefining Precision Management of r/r Large B-Cell Lymphoma: Novel Antibodies Take on CART and BMT in the Quest for Future Treatment Strategies.
Dada R
Cells; 2023 Jul; 12(14):. PubMed ID: 37508523
[TBL] [Abstract][Full Text] [Related]
6. New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia.
Jordaens S; Cooksey L; Freire Boullosa L; Van Tendeloo V; Smits E; Mills KI; Orchard KH; Guinn BA
Cancer Immunol Immunother; 2020 May; 69(5):867-877. PubMed ID: 31970440
[TBL] [Abstract][Full Text] [Related]
7. Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia.
Tadmor T; Levy Yurkovski I
Leuk Lymphoma; 2024 May; 65(5):684-687. PubMed ID: 38247446
[No Abstract] [Full Text] [Related]
8. The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives.
Caracciolo D; Mancuso A; Polerà N; Froio C; D'Aquino G; Riillo C; Tagliaferri P; Tassone P
Exp Hematol Oncol; 2023 Jan; 12(1):5. PubMed ID: 36624522
[TBL] [Abstract][Full Text] [Related]
9. Bispecific Antibodies in Hematological Malignancies: A Scoping Review.
Omer MH; Shafqat A; Ahmad O; Alkattan K; Yaqinuddin A; Damlaj M
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760519
[TBL] [Abstract][Full Text] [Related]
10. Bispecific T cell engager therapy for refractory rheumatoid arthritis.
Bucci L; Hagen M; Rothe T; Raimondo MG; Fagni F; Tur C; Wirsching A; Wacker J; Wilhelm A; Auger JP; Pachowsky M; Eckstein M; Alivernini S; Zoli A; Krönke G; Uderhardt S; Bozec A; D'Agostino MA; Schett G; Grieshaber-Bouyer R
Nat Med; 2024 Apr; ():. PubMed ID: 38671240
[TBL] [Abstract][Full Text] [Related]
11. The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies.
Yang C; Lou G; Jin WL
Signal Transduct Target Ther; 2021 Jun; 6(1):219. PubMed ID: 34083505
[No Abstract] [Full Text] [Related]
12. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
[TBL] [Abstract][Full Text] [Related]
13. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.
Locatelli F; Whitlock JA; Peters C; Chen-Santel C; Chia V; Dennis RM; Heym KM; Katz AJ; Kelsh MA; Sposto R; Tu H; Tuglus CA; Verma A; Vinti L; Wilkes JJ; Zubarovskaja N; Zugmaier G; von Stackelberg A; Sun W
Leukemia; 2020 Sep; 34(9):2473-2478. PubMed ID: 32094465
[No Abstract] [Full Text] [Related]
14. B Cells versus T Cells in the Tumor Microenvironment of Malignant Lymphomas. Are the Lymphocytes Playing the Roles of Muhammad Ali versus George Foreman in Zaire 1974?
Desmirean M; Rauch S; Jurj A; Pasca S; Iluta S; Teodorescu P; Berce C; Zimta AA; Turcas C; Tigu AB; Moldovan C; Paris I; Steinheber J; Richlitzki C; Constantinescu C; Sigurjonsson OE; Dima D; Petrushev B; Tomuleasa C
J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33114418
[TBL] [Abstract][Full Text] [Related]
15. Recent updates for antibody therapy for acute lymphoblastic leukemia.
Li L; Wang Y
Exp Hematol Oncol; 2020 Nov; 9(1):33. PubMed ID: 33292550
[TBL] [Abstract][Full Text] [Related]
16. Brief overview of antibody-drug conjugate therapy for acute leukemia.
Walter RB
Expert Opin Biol Ther; 2021 Jul; 21(7):795-799. PubMed ID: 32857943
[No Abstract] [Full Text] [Related]
17. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
Samra B; Jabbour E; Ravandi F; Kantarjian H; Short NJ
J Hematol Oncol; 2020 Jun; 13(1):70. PubMed ID: 32503572
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia.
Barsan V; Ramakrishna S; Davis KL
Curr Oncol Rep; 2020 Jan; 22(2):11. PubMed ID: 31997022
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.
Li X; Tian W; Jiang Z; Song Y; Leng X; Yu J
Cancer Immunol Immunother; 2024 Jan; 73(2):31. PubMed ID: 38279998
[TBL] [Abstract][Full Text] [Related]
20. Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next?
Tannoury M; Garnier D; Susin SA; Bauvois B
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
